Hairy Cell Leukemia: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Hairy cell leukemia (HCL) is a rare, indolent mature B-cell lymphoma characterized by neoplastic B-cells with characteristic hair-like cytoplasmic projections visible on peripheral blood smear, accounting for approximately 2% of adult leukemias with approximately 1,000 new US cases per year. It predominantly affects middle-aged white males, with a median age at diagnosis of 55 years and a male-to-female ratio of 4:1. BRAF V600E somatic mutation — the same activating BRAF mutation found in melanoma and papillary thyroid cancer — is present in over 95% of classic HCL cases and serves as the pathognomonic molecular marker, enabling definitive diagnosis and therapeutic targeting. HCL behaves as a chronic indolent lymphoma with a natural history of progressive cytopenia from bone marrow infiltration and splenomegaly. Despite its incurability with standard therapies, HCL has an excellent prognosis: modern treatment with purine analogues achieves long-term disease control, and 10-year overall survival exceeds 95%.

The defining molecular event in classic HCL is the BRAF V600E somatic point mutation (valine to glutamic acid at codon 600), which constitutively activates the MAPK signaling cascade independent of upstream RAS signaling, driving B-cell proliferation and survival. This mutation is present in virtually all cases of classic HCL and represents an ideal diagnostic marker and therapeutic target. IGHV4-34 immunoglobulin heavy chain usage characterizes HCL variant — a distinct and more aggressive entity that lacks BRAF V600E and is resistant to standard cladribine therapy. MAP2K1 (MEK1) mutations are found in some BRAF-wildtype HCL cases. No confirmed germline predisposition syndrome or hereditary risk factor for classic HCL has been identified. Occupational exposures to organophosphate pesticides, herbicides, and radiation have been proposed as risk factors in some epidemiological studies, though evidence remains inconclusive.

The clinical presentation of HCL is dominated by cytopenias from bone marrow infiltration and hypersplenism. Fatigue and exercise intolerance from anemia are the most common presenting symptoms. Recurrent bacterial and opportunistic infections from neutropenia and monocytopenia — the characteristic immune deficiency of HCL — manifest as pneumonia, urinary tract infections, and severe or atypical infections including Mycobacterium avium complex, Legionella, and Pneumocystis jirovecii. Thrombocytopenia causes easy bruising and bleeding tendency. Massive splenomegaly is the characteristic physical finding, often causing left upper quadrant fullness, early satiety, and left shoulder pain. Lymphadenopathy is uncommon in classic HCL, distinguishing it from other B-cell lymphomas. 'Dry tap' (inability to aspirate bone marrow despite adequate technique) due to extensive reticulin fibrosis is a clinical hallmark.

Peripheral blood morphology demonstrates hairy cells: medium-to-large lymphocytes with abundant pale cytoplasm, irregular hair-like cytoplasmic projections, and oval or bean-shaped nuclei with condensed chromatin and indistinct nucleoli. Hairy cells are positive for tartrate-resistant acid phosphatase (TRAP) stain. Flow cytometry of peripheral blood is diagnostic, showing a mature B-cell immunophenotype: CD19+, CD20+, CD22+, CD11c (bright)+, CD25+, CD103+, CD123+, CD200+, and annexin A1+ — the combination of CD11c, CD25, CD103, and CD123 is highly specific for HCL. BRAF V600E mutation testing by allele-specific PCR or immunohistochemistry confirms classic HCL. Bone marrow trephine biopsy demonstrates interstitial to diffuse infiltration of hairy cells with a characteristic fried-egg appearance on reticulin stain with surrounding clear cytoplasm halos. CT abdomen evaluates splenomegaly and lymphadenopathy. Monocytopenia (absolute monocyte count under 100/μL) is a diagnostically useful and characteristic finding in HCL, distinct from other B-cell lymphomas.

Treatment is initiated when cytopenias are symptomatic: hemoglobin under 11 g/dL, neutrophils under 1.0×10^9/L, platelets under 100×10^9/L, symptomatic splenomegaly, or recurrent serious infections. Cladribine (2-chlorodeoxyadenosine, 2-CdA) is the standard first-line treatment: 0.09–0.1 mg/kg/day as a 7-day continuous IV infusion (or weekly SC administration × 6 doses). A single course achieves complete remission in 80–90% of patients with a median duration of complete remission of 7–10 years. Pentostatin (deoxycoformycin, 4 mg/m2 every 2 weeks × 6–12 doses) is equally effective and is the preferred agent for patients with renal impairment. Adding rituximab (anti-CD20, 375 mg/m2 weekly × 8 doses) concurrently or after cladribine achieves MRD-negative complete remission in approximately 95% and may prolong disease-free survival. Relapsed/refractory HCL: retreatment with cladribine or pentostatin achieves second CR in 75–80%; BRAF V600E-targeted therapy with vemurafenib or dabrafenib achieves high ORR in BRAF-mutant relapsed disease; moxetumomab pasudotox (anti-CD22 immunotoxin) is FDA-approved for multiple-relapsed HCL.

HCL has an excellent prognosis with modern treatment. Ten-year overall survival exceeds 95%. Most patients achieve complete remission after a single course of cladribine, which is maintained for a median of 7–10 years. Relapse occurs in approximately 40–50% of patients at 10 years but responds well to re-treatment (second CR rate approximately 75–80%). BRAF inhibitors provide an effective salvage option after purine analogue failure. HCL variant — defined by IGHV4-34 expression without BRAF V600E — has a substantially worse prognosis and requires different treatment approaches. Life expectancy for patients with classic HCL is near-normal with appropriate long-term disease monitoring and treatment of relapses.

No established preventive strategies exist for hairy cell leukemia, as the causative BRAF V600E somatic mutation arises sporadically without known environmental triggers. There is no hereditary predisposition and no recommendation for family screening. Prophylactic antimicrobial agents (trimethoprim-sulfamethoxazole for Pneumocystis pneumonia prophylaxis, macrolide antibiotics for MAC prophylaxis) are administered to patients receiving cladribine therapy during the period of neutropenia and CD4+ T-cell depletion that follows treatment. G-CSF (filgrastim) is used to support neutrophil recovery after cladribine in patients with severe pre-treatment neutropenia or febrile neutropenia during treatment. Patients should be vaccinated against pneumococcus, influenza, and COVID-19 before starting therapy. Regular follow-up CBC every 3–6 months during remission detects early relapse. Prompt evaluation of unexplained cytopenias, splenomegaly, or recurrent infections in middle-aged adults should include bone marrow assessment.

Consult a hematologist promptly if a routine blood count reveals unexplained low blood cell counts — particularly anemia, low white cell count, or low platelets — without an obvious cause. Persistent fatigue, pallor, or exertional shortness of breath in a middle-aged adult with a gradually enlarging left-sided abdominal fullness warrants blood count and abdominal imaging to assess for splenomegaly. Recurrent or unusually severe bacterial infections, atypical infections (lung infections with organisms not normally pathogenic), or infections requiring hospitalization despite adequate immune function suggest underlying immune deficiency such as HCL. A blood smear request should specifically note 'evaluate for hairy cells' when HCL is suspected. Any patient with known HCL who develops worsening fatigue, increasing frequency of infections, bruising, or worsening splenomegaly should notify their hematologist without waiting for the next scheduled appointment, as these symptoms may indicate relapse or disease progression requiring treatment.